Published in N Engl J Med on June 19, 2014
Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA (2015) 3.20
Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study. Eur J Epidemiol (2015) 2.17
Statins and congenital malformations: cohort study. BMJ (2015) 1.75
Case-control studies require appropriate population controls: an example of error in the SSRI birth defect literature. Eur J Epidemiol (2015) 1.13
Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 1.05
Women's perception of risks of adverse fetal pregnancy outcomes: a large-scale multinational survey. BMJ Open (2015) 1.01
Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 0.98
Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations. JAMA Psychiatry (2016) 0.90
Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies. Br J Clin Pharmacol (2017) 0.88
Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr (2015) 0.87
Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 0.84
Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data. Pharmacoepidemiol Drug Saf (2015) 0.81
HIV Infection Itself May Not Be Associated With Subclinical Coronary Artery Disease Among African Americans Without Cardiovascular Symptoms. J Am Heart Assoc (2016) 0.81
Meta-analysis requires independent observations and freedom from bias. Br J Clin Pharmacol (2016) 0.80
Optimizing the treatment of mood disorders in the perinatal period. Dialogues Clin Neurosci (2015) 0.79
Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges. Expert Opin Drug Saf (2016) 0.79
Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta-Analysis of Prospective Cohort Studies. J Am Heart Assoc (2015) 0.79
Use of SSRI and SNRI Antidepressants during Pregnancy: A Population-Based Study from Denmark, Iceland, Norway and Sweden. PLoS One (2015) 0.78
Maternal serum cadmium level during pregnancy and its association with small for gestational age infants: a population-based birth cohort study. Sci Rep (2016) 0.77
Depression and antidepressants in pregnancy: molecular and psychosocial mechanisms affecting offspring's physical and mental health. Neuropsychopharmacology (2015) 0.77
Neurotransmitter signaling pathways required for normal development in Xenopus laevis embryos: a pharmacological survey screen. J Anat (2016) 0.76
Treating perinatal depression: risks and stigma. Obstet Gynecol (2014) 0.76
Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations. Obstet Gynecol (2016) 0.75
Calcium Channel Blocker Exposure in Late Pregnancy and the Risk of Neonatal Seizures. Obstet Gynecol (2015) 0.75
Promise and peril: Dissemination of findings from studies of drugs used in pregnancy and their association with birth defects. Birth Defects Res A Clin Mol Teratol (2015) 0.75
Cardiac dysfunction and prenatal exposure to venlafaxine. Clin Case Rep (2016) 0.75
Paroxetine-The Antidepressant from Hell? Probably Not, But Caution Required. Psychopharmacol Bull (2016) 0.75
Paroxetine use during pregnancy and the risk of cardiac defects. Br J Clin Pharmacol (2016) 0.75
Constructing Causal Diagrams for Common Perinatal Outcomes: Benefits, Limitations and Motivating Examples with Maternal Antidepressant Use in Pregnancy. Paediatr Perinat Epidemiol (2016) 0.75
[Which antidepressants to use during pregnancy?]. Soins Pediatr Pueric (2014) 0.75
Recent Advances and Controversies in Peripartum Depression. Curr Obstet Gynecol Rep (2016) 0.75
Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark. PLoS One (2016) 0.75
Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open (2017) 0.75
Clinical management of medications in pregnancy and lactation. Am J Obstet Gynecol (2016) 0.75
Probabilistic bias analysis in pharmacoepidemiology and comparative effectiveness research: a systematic review. Pharmacoepidemiol Drug Saf (2016) 0.75
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key? Int J Mol Sci (2016) 0.75
Diagnosing and Treating Depression During Pregnancy. Prim Care Companion CNS Disord (2015) 0.75
Antidepressant exposure during the first trimester does not increase the risk of cardiac malformations in infants. Evid Based Ment Health (2014) 0.75
Is third trimester serotonin reuptake inhibitor use associated with postpartum hemorrhage? J Psychiatr Res (2015) 0.75
Serotonin Transporter Protects the Placental Cells Against Apoptosis in Caspase 3-Independent Pathway. J Cell Physiol (2017) 0.75
The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies. Eur J Clin Pharmacol (2017) 0.75
Zidovudine use in pregnancy and congenital malformations: meta-analysis and Bayesian incorporation of medicaid data. AIDS (2017) 0.75
Cardiac Outcomes after Perinatal Sertraline Exposure in Mice. J Cardiovasc Pharmacol (2017) 0.75
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol (2001) 7.04
Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ (2009) 6.83
Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA (2006) 6.48
Cohort study of depressed mood during pregnancy and after childbirth. BMJ (2001) 6.09
A method to automate probabilistic sensitivity analyses of misclassified binary variables. Int J Epidemiol (2005) 5.17
Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med (2002) 4.38
First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med (2007) 4.25
Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med (2007) 3.79
First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol (2010) 3.45
Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol (2011) 3.42
Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology (2006) 3.23
Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol (2007) 2.61
First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol (2007) 2.06
Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf (2007) 2.04
Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol (2007) 2.02
Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry (2008) 2.01
Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol (2008) 2.00
Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther (2007) 1.98
Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol (2005) 1.96
Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiol Drug Saf (2012) 1.81
Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations. PLoS One (2013) 1.74
Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol (2006) 1.56
Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol (2012) 1.40
National trends in antidepressant medication treatment among publicly insured pregnant women. Gen Hosp Psychiatry (2013) 1.36
Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc (2009) 1.27
Teratogenicity of SSRIs--serious concern or much ado about little? N Engl J Med (2007) 1.22
Validity of maternal and infant outcomes within nationwide Medicaid data. Pharmacoepidemiol Drug Saf (2014) 1.19
Pregnancy outcome after in utero exposure to valproate : evidence of dose relationship in teratogenic effect. CNS Drugs (2008) 1.03
Using ICD-9 codes to establish prevalence of malformations in newborn infants. Birth Defects Res A Clin Mol Teratol (2012) 0.92
The effect of ascertainment bias in evaluating gestational antidepressant exposure. J Popul Ther Clin Pharmacol (2011) 0.90
A structural approach to selection bias. Epidemiology (2004) 16.44
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol (2002) 9.76
A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol (2005) 8.77
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis*. Crit Care Med (2014) 5.89
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47
New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med (2010) 4.27
First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med (2007) 4.25
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ (2013) 3.88
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82
The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78
Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol (2003) 3.75
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64
Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62
Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43
Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol (2011) 3.42
Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry (2007) 3.40
The quality of pharmacologic care for vulnerable older patients. Ann Intern Med (2004) 3.34
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ (2007) 3.30
The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27
Rethinking the use of physicians as hired expert lecturers. Ann Intern Med (2014) 3.22
Drug-review deadlines and safety problems. N Engl J Med (2008) 3.16
Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med (2009) 3.08
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA (2005) 2.95
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Hetastarch and bleeding complications after coronary artery surgery. Chest (2003) 2.87
Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81
Internet marketing of herbal products. JAMA (2003) 2.77
Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA (2004) 2.77
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74
The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med (2010) 2.71
Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA (2011) 2.70
Sending pharma better signals. Science (2005) 2.69
Beyond the intention-to-treat in comparative effectiveness research. Clin Trials (2011) 2.65
Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65
Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res (2003) 2.65
The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol (2011) 2.61
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA (2011) 2.60
Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58
Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med (2015) 2.53
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med (2004) 2.52
Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation (2008) 2.42
Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GLI3 mutations. Am J Hum Genet (2005) 2.40
Identification of phthalates in medications and dietary supplement formulations in the United States and Canada. Environ Health Perspect (2011) 2.40
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis (2010) 2.39
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology (2005) 2.38
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.37
Racial differences in screening for prostate cancer in the elderly. Arch Intern Med (2004) 2.34
Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care (2007) 2.31
Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. Arthritis Rheum (2003) 2.30
Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther (2011) 2.24
Commentary: A structural approach to Berkson's fallacy and a guide to a history of opinions about it. Int J Epidemiol (2014) 2.23
Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum (2007) 2.18
Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol (2002) 2.15
Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med (2012) 2.13
Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making (2006) 2.12